US2012276116A1PendingUtilityA1
Prevention and Treatment of Amyloidogenic Disease
Est. expiryDec 2, 2017(expired)· nominal 20-yr term from priority
Inventors:Dale B. Schenk
A61P 43/00A61P 37/00A61P 25/00A61P 25/28A61K 31/739A61K 2039/53A61K 38/193A61K 2039/505A61K 9/2031C07K 16/18A61K 9/4866C07K 14/4711A61K 2039/55505A61K 9/7023A61K 47/646A61K 39/0007A61K 2039/55577A61K 9/0019A61K 2039/605A61K 38/1709C07K 2317/567C07K 2319/00A61K 9/2009A61K 2039/55555A61K 2039/55566A61K 31/00A61K 2039/55572A61K 2039/6037C07K 2317/24A61K 9/2054A61K 39/00
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide, active fragments thereof or an antibody thereto.
Claims
exact text as granted — not AI-modified1 . A method of preventing or treating a disease characterized by amyloid deposit in a patient, comprising administering an effective dosage of an antibody that specifically binds to the amyloid deposit or a component thereof to the patient.
2 - 37 . (canceled)
38 . A method of preventing or treating Alzheimer's disease, comprising administering an effective dosage of a polypeptide comprising an active fragment of Aβ that induces an immune response to Aβ in the patient.
39 - 52 . (canceled)
53 . A pharmaceutical composition comprising an active fragment of Aβ effective to induce a response to AB in a patient and an adjuvant.
54 - 163 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.